aibioVivoSim Labs receives Nasdaq bid price notice with February 2027 deadline
Tickers VIVS
Nasdaq staff said VivoSim Labs has until February 16, 2027 to show a closing bid price of at least $1 for ten consecutive business days, and the company is weighing a reverse split.
Key facts
- Company
- VivoSim Labs, INC. (NASDAQ: VIVS)
- News type
- Listings
- Primary source
- VivoSim Labs, INC. 8-K (2026-08-21)
VivoSim Labs, Inc. (Nasdaq: VIVS) received a written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC on August 17, 2026. The notice said the company's common stock no longer met the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2), based on the closing bid price over the last 30 consecutive business days. The company disclosed the notice in an 8-K filing dated August 21, 2026. The notice has no immediate effect on the listing or trading of the common stock, which continues to trade on the Nasdaq Capital Market under the symbol VIVS.
The compliance period
Nasdaq gave the company an initial period of 180 calendar days, or until February 16, 2027, to regain compliance, under Nasdaq Listing Rule 5810(c)(3)(A). To regain compliance, the closing bid price must be at least $1 per share for a minimum of ten consecutive business days during that period.
If the company does not regain compliance by February 16, 2027, it may be eligible for an additional compliance period of 180 calendar days. To qualify, it would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except the bid price requirement. If the Staff determines that the company cannot cure the deficiency, or that it is not eligible, Nasdaq would notify the company that its securities will be subject to delisting. The company could then appeal that determination, but the filing says there can be no assurance the Staff would grant any request for continued listing.
The company said it intends to monitor the closing bid price and consider its available options if the stock does not trade at a level likely to restore compliance by February 16, 2027. Those options include a reverse stock split, which would need prior approval from stockholders.
The reverse split proposal
The company's preliminary proxy statement for its 2026 Annual Meeting of Stockholders was filed with the Securities and Exchange Commission on August 10, 2026. The proxy includes a proposal to effect a reverse stock split at a ratio the Board of Directors sets within a range of 1-for-5 to 1-for-20. The company said that if stockholders approve the proposal and the split is implemented, it believes it would regain compliance with the bid price rule. The filing gives no assurance of approval, of the split, of compliance or of other listing requirements.
The business and financial position
VivoSim Labs describes itself as a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights using new approach methodologies, or NAM, models.
The company sold its FXR program in March 2025 for $10.0 million, with $9.0 million paid at closing and $1.0 million held in escrow for 15 months. It received a $5.0 million milestone payment in July 2026. For the fiscal year ended March 31, 2026, research and development expense was $4.2 million, compared with $5.0 million for fiscal 2025. The company reported a net loss of $13.8 million, against $2.5 million, and cash from operations of negative $10.8 million, against negative $9.5 million. Year-end cash and cash equivalents were $11.3 million for fiscal 2025. Cash and cash equivalents were $1.7 million at June 30, 2026, according to a quarterly report on Form 10-Q.
What comes next
The company's stated next steps are to monitor the bid price, decide whether to pursue a reverse split, and work toward the stockholder vote described in its proxy statement. The first deadline in the notice is February 16, 2027.
A reverse split would change the share price, not the finances. The net loss rose to $13.8 million from $2.5 million, and cash was $1.7 million at June 30, 2026, before the $5.0 million milestone received in July. The sources give no revenue figure for the testing business, and the remaining $50.0 million of FXR314 milestones depend on development the company sold.